True. $CLDN first stated that they were still on track for data at end of APR but then started talking about the possible need for another clinical trial. With these prices, investors got pretty skittish.
Reverse every natural instinct and do the opposite of what you are inclined to do, and you will probably come very close to having a perfect golf swing. Ben Hogan
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.